Sitagliptin, by inhibiting DPP-4, enhances incretin hormone activity, which improves beta-cell function and glucose regulation, thus boosting dietary intervention effects in diabetes management.

Sitagliptin aids in glucose management in diabetic patients through DPP-4 inhibition which increases incretin levels, enhancing the effects of diet-based interventions by improving postprandial glycemic control.